VIDEO: Alirocumab study showing sharp reduction in MACE promising but not definitive

CHICAGO – Discussant Dr. Robert M. Califf called the results of the ODYSSEY LONG TERM trial presented by Dr. Jennifer G. Robinson at the annual congress of the European Society of Cardiology "alluring" and "fantastic," with a reported 54% reduction in major adverse cardiovascular events in high-risk, statin-treated patients on add-on alirocumab. But neither he nor Dr. Robinson consider these results to be the final word on the subject.

Here’s what Dr. Robinson had to say about the investigational PCSK9 inhibitor’s performance in the study. 

bjancin@frontlinemedcom.com

CHICAGO – Discussant Dr. Robert M. Califf called the results of the ODYSSEY LONG TERM trial presented by Dr. Jennifer G. Robinson at the annual congress of the European Society of Cardiology "alluring" and "fantastic," with a reported 54% reduction in major adverse cardiovascular events in high-risk, statin-treated patients on add-on alirocumab. But neither he nor Dr. Robinson consider these results to be the final word on the subject.

Here’s what Dr. Robinson had to say about the investigational PCSK9 inhibitor’s performance in the study. 

bjancin@frontlinemedcom.com

CHICAGO – Discussant Dr. Robert M. Califf called the results of the ODYSSEY LONG TERM trial presented by Dr. Jennifer G. Robinson at the annual congress of the European Society of Cardiology "alluring" and "fantastic," with a reported 54% reduction in major adverse cardiovascular events in high-risk, statin-treated patients on add-on alirocumab. But neither he nor Dr. Robinson consider these results to be the final word on the subject.

Here’s what Dr. Robinson had to say about the investigational PCSK9 inhibitor’s performance in the study. 

bjancin@frontlinemedcom.com